193 related articles for article (PubMed ID: 34794541)
1. Antisense oligonucleotide technology as a research tool in plant biology.
Wdowikowska A; Janicka M
Funct Plant Biol; 2021 Dec; 49(1):1-12. PubMed ID: 34794541
[TBL] [Abstract][Full Text] [Related]
2. Efficient Gene Suppression by DNA/DNA Double-Stranded Oligonucleotide In Vivo.
Asami Y; Nagata T; Yoshioka K; Kunieda T; Yoshida-Tanaka K; Bennett CF; Seth PP; Yokota T
Mol Ther; 2021 Feb; 29(2):838-847. PubMed ID: 33290725
[TBL] [Abstract][Full Text] [Related]
3. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.
Oberemok VV; Laikova KV; Repetskaya AI; Kenyo IM; Gorlov MV; Kasich IN; Krasnodubets AM; Gal'chinsky NV; Fomochkina II; Zaitsev AS; Bekirova VV; Seidosmanova EE; Dydik KI; Meshcheryakova AO; Nazarov SA; Smagliy NN; Chelengerova EL; Kulanova AA; Deri K; Subbotkin MV; Useinov RZ; Shumskykh MN; Kubyshkin AV
Molecules; 2018 May; 23(6):. PubMed ID: 29844255
[TBL] [Abstract][Full Text] [Related]
4. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides: from design to therapeutic application.
Chan JH; Lim S; Wong WS
Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
[TBL] [Abstract][Full Text] [Related]
6. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
Zhao X; Pan F; Holt CM; Lewis AL; Lu JR
Expert Opin Drug Deliv; 2009 Jul; 6(7):673-86. PubMed ID: 19552611
[TBL] [Abstract][Full Text] [Related]
7. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
[TBL] [Abstract][Full Text] [Related]
8. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
9. Antisense technology: an overview and prospectus.
Crooke ST; Baker BF; Crooke RM; Liang XH
Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
12. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis.
Dong L; Zuo L; Xia S; Gao S; Zhang C; Chen J; Zhang J
J Gene Med; 2009 Mar; 11(3):229-39. PubMed ID: 19189285
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide technology can be used to investigate a circular but not linear RNA-mediated function for its encoded gene locus.
Song Z; Jia R; Tang M; Xia F; Xu H; Li Z; Huang C
Sci China Life Sci; 2021 May; 64(5):784-794. PubMed ID: 32815066
[TBL] [Abstract][Full Text] [Related]
14. GOLGA8 increases bulk antisense oligonucleotide uptake and activity in mammalian cells.
McMahon MA; Rahdar M; Mukhopadhyay S; Bui HH; Hart C; Damle S; Courtney M; Baughn MW; Cleveland DW; Bennett CF
Mol Ther Nucleic Acids; 2023 Jun; 32():289-301. PubMed ID: 37096163
[TBL] [Abstract][Full Text] [Related]
15. DNA-RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing.
Hara RI; Yoshioka K; Yokota T
Methods Mol Biol; 2020; 2176():113-119. PubMed ID: 32865786
[TBL] [Abstract][Full Text] [Related]
16. Quantification of Antisense Oligonucleotides by Splint Ligation and Quantitative Polymerase Chain Reaction.
Shin M; Meda Krishnamurthy P; Devi G; Watts JK
Nucleic Acid Ther; 2022 Feb; 32(1):66-73. PubMed ID: 34928745
[TBL] [Abstract][Full Text] [Related]
17. Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension.
Yasuhara H; Yoshida T; Sasaki K; Obika S; Inoue T
Mol Diagn Ther; 2022 Jan; 26(1):117-127. PubMed ID: 34994962
[TBL] [Abstract][Full Text] [Related]
18. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery.
Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C
Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biophysical properties of tetravalent PEG-conjugated antisense oligonucleotide.
Rahman Chowdhury T; Taufiq T; Ishida K; Ariful Islam M; Kasahara Y; Osawa T; Obika S
Bioorg Med Chem; 2023 Jan; 78():117149. PubMed ID: 36587552
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
